Ignasi Pau-Charles

Ignasi Pau-Charles began their career in 2009 at Hospital Clínic de Barcelona, where they completed a Dermatology Residency Training Program from 2009 to 2013. Ignasi then worked as a Researcher from 2013 to 2015. In 2014, they transitioned to Almirall, starting as a Global Medical Advisor and eventually progressing to roles such as Medical Affairs Manager, EU Medical Affairs Lead for Tildrakizumab and Lebrikizumab, Global Medical Immunology Manager, Global Medical Director - Immunology, and Global Medical Affairs Senior Director. As of 2023, they hold the position of Global Medical Affairs Executive Director at Almirall.

Ignasi Pau-Charles completed their Doctor of Medicine degree at Universitat Rovira i Virgili in 2008. Ignasi pursued various fellowships in Pediatric Dermatology, Radiology, and Intensive Care Unit at different institutions. Ignasi completed their Dermatology residency at Universitat de Barcelona in 2013 and also obtained a Research Doctorate in Cutaneous T-Cell Lymphoma from the same institution in 2015. In 2019, Ignasi further expanded their knowledge by completing a course in Business Acumen for Medical Science Liaisons at CELforPharma.